For most Australians, $420,000 is the kind of money that takes years — sometimes decades — to accumulate. It is a house deposit in many parts of the country (admittedly, a modest one in Sydney). It is a decade of diligent saving for the average full-time worker. For more than 100 employees at Eucalyptus, the Sydney-founded digital health startup, something close to that figure has materialised virtually overnight — the direct result of a $1.6 billion acquisition that has sent quiet ripples of celebration through Australia's technology sector.
The deal triggered a windfall for employee shareholders who had accepted equity as part of their remuneration packages — in many cases, in lieu of the higher salaries they might have commanded at more established firms. In plain English, this means: they bet on the company, and the bet paid off handsomely.
The mechanics of an overnight fortune
Employee equity — shares granted to workers, usually with vesting conditions that require staying at the company for a set period — has long been the currency of the startup world. The pitch is straightforward: accept a lower base salary now, hold some equity, and if the company succeeds, you benefit proportionally. The risk, of course, is considerable. Most startups fail, and the equity they hand out ultimately proves worth little more than a line on a résumé.
Eucalyptus, which built a telehealth platform offering subscription-based access to medical professionals and treatments across a range of health concerns, managed to beat those odds. Founded in 2019, the company grew rapidly through the pandemic years as Australians embraced digital health services — a sector that has since become a permanent fixture of the healthcare landscape rather than a temporary workaround.
A vote of confidence for Australian innovation
From a centre-right perspective, stories like this represent the market working as intended. Entrepreneurs take risks, investors back them, workers accept deferred compensation, and — when it works — everyone shares in the upside. The $1.6 billion valuation is not just a windfall for employees; it is a signal to the broader market that Australian healthcare technology can attract serious capital and serious interest.
There is also a structural argument here about talent retention. Australia has historically struggled to keep its brightest people at home, with engineers, scientists, and entrepreneurs frequently departing for Silicon Valley, London, or Singapore in search of higher salaries and more mature startup ecosystems. High-profile acquisition events like this one create a compelling counter-narrative: you can build something genuinely valuable here, and you can be rewarded for it here.
The other side of the ledger
It would be incomplete journalism to present this as an uncomplicated triumph without acknowledging the messier reality of startup equity culture.
For every Eucalyptus, there are dozens of companies whose employees took comparable bets and walked away with nothing. Equity packages can be structured in ways that quietly disadvantage workers — through preference share arrangements that pay investors first, or liquidation clauses that erode the value of ordinary shares when an acquisition price falls short of expectations. Workers without financial or legal literacy may not fully understand what they are agreeing to when they accept equity as part of their compensation.
Progressive economists and labour advocates have long argued that startup equity culture can exploit the optimism of young workers, offering uncertain future rewards in place of present-day wages and superannuation contributions. That is not a frivolous concern. The $420,000 outcome for Eucalyptus employees is the exception, not the rule — and policy frameworks that better protect workers navigating these arrangements would serve the broader public interest.
What this means for the ecosystem
The honest answer about what this acquisition means for Australian startups long-term is that nobody knows for certain. Big exit events tend to do two things simultaneously: they inspire a new generation of founders and employees to take the plunge, and they quietly remind everyone that outcomes of this scale remain rare.
What is clear is that Australia's digital health sector has matured considerably, and investor appetite for well-run, scalable healthcare platforms is strong. The federal government's ongoing investment in digital health infrastructure — through Medicare-linked systems and related programmes — has created fertile ground for private innovation to take root alongside public provision.
For the more than 100 Eucalyptus employees now weighing their options — whether that means paying down a mortgage, seeding their own venture, or simply booking a long-overdue holiday — the windfall represents something genuinely worth celebrating. The startup bet, this time, paid off.
Originally reported by 9News.